The impact of extraction protocol on the chemical profile of cannabis extracts from a single cultivar
Contents
Appearance
![]() | |
Names | |
---|---|
IUPAC name
4-[3-(6-phenylpyridin-3-yl)-5-propan-2-yl-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C22H18N6O | |
Molar mass | 382.427 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
ASP2535 is an inhibitor of the type 1 glycine transporter.[1] It could potentially be used in treatment of Alzheimer's disease and schizophrenia.
Potential uses
ASP2535 has been investigated for the treatment of Alzheimer's disease and schizophrenia, it is able to inhibit the memory deficit induced by scopolamine, an anticholinergic agent.[1]
References
- ^ a b Harada, Katsuya; Nakato, Kazuhiro; Yarimizu, Junko; Yamazaki, Mayako; Morita, Masahiko; Takahashi, Shinji; Aota, Masaki; Saita, Kyoko; Doihara, Hitoshi; Sato, Yuichiro; Yamaji, Takayuki; Ni, Keni; Matsuoka, Nobuya (2012-06-15). "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease". European Journal of Pharmacology. 685 (1–3): 59–69. doi:10.1016/j.ejphar.2012.04.013. ISSN 1879-0712. PMID 22542656.